AI-engineered nano-vaccines to counter antimicrobial resistance in immunosuppressed and oncologic populations - Letter to the Editor

Sep 29, 2026

Antimicrobial resistance (AMR) remains a major post-pandemic threat, especially for immunosuppressed and oncologic populations where impaired immunity and broad antibiotic exposure converge. The letter notes that AMR causes about 1.27 million deaths annually and threatens nearly half of hospitalized cancer patients. It argues that AI-engineered nano-vaccines can predict antigen targets with high epitope-mapping accuracy and deliver targeted immunity even in compromised hosts, showing stronger antibody responses and reduced resistant colonization in early studies.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages2

Reading Time5 min

AccessFree to download

Letter to the Editor

Abstract

To the Editor

Use of generative AI and AI-assisted technologies

Clinical trial registration

Ethical approval

Consent

Sources of funding

Author contributions

Conflicts of interest disclosure

Letter to the Editor AI-engineered nano-vaccines to counter antimicrobial resistance in immunosuppressed and oncologic populations Muhammad Shahid Mehmood, MPhila , Fatima Hajj, MDb ,* Abstract Antimicrobial resistance (AMR) remains one of the most pressing post-pandemic threats, particularly in immunosuppressed and oncologic populations where immune dysfunction and broad-spectrum antibiotic exposure converge. Globally, more than 1.27 million deaths each year are directly attributed to AMR, with resistant infections affecting nearly half of hospitalized cancer patients. Traditional antibiotic stewardship has proven insufficient, prompting exploration of AI-engineered nano-vaccines as an innovative prophylactic solution. These platforms integrate artificial intelligence for antigen prediction with nanoparticle-based delivery to stimulate targeted immunity even in compromised hosts. Preclinical studies demonstrate over 90% accuracy in epitope mapping and up to a 12-fold increase in antibody titers compared to conventional vaccines. Early translational trials in postchemotherapy cohorts show a 60% reduction in resistant bacterial colonization, highlighting their preventive potential. AI-driven nano-immunization represents a transformative strategy to restore antimicrobial protection in high-risk patient populations and mitigate the expanding global AMR crisis. Keywords: antimicrobial resistance, artificial intelligence, immunosuppression, nano-vaccines, oncologic infections To the Editor, Antimicrobial resistance has become a parallel pandemic, responsible for approximately 1.27 million deaths annually and contributing to nearly 4.95 million deaths worldwide[1] . Immunosuppressed and oncologic patients represent one of the most vulnerable cohorts, with up to 52% of hospitalized cancer patients developing multidrug-resistant infections and mortality rates exceeding 35%[2]. Chemotherapy, stem cell transplantation, and immune checkpoint inhibition collectively weaken host defense, creating a microbial niche where resistant pathogens thrive[3]. Recent advances in artificial intelligence (AI) and nanotechnology have opened new horizons for infection prevention through AIengineered nano-vaccines platforms capable of integrating real-time genomic data to predict antigenic targets with over 90% precision[4]. Machine learning algorithms have already identified conserved epitopes across Klebsiella pneumoniae, Pseudomonas aInstitute of Microbiology, University of Agriculture Faisalabad, Faisalabad, Pakistan and bFaculty of Medical Sciences, Lebanese University, Beirut, Lebanon Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. *Corresponding author. Address: Faculty of Medical Sciences, Lebanese University, P.O. Box 6573/14, Beirut, Lebanon. Tel.:+961 81001507. E-mail: [fatimalalala2001@gmail.com](fatimalalala2001@gmail.com) (F. Hajj). Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Annals of Medicine & Surgery (2026) 88:1026–1027 Received 14 October 2025; Accepted 10 November 2025 Published online 24 November 2025 [http://dx.doi.org/10.1097/MS9.0000000000004380](http://dx.doi.org/10.1097/MS9.0000000000004380) aeruginosa, and Acinetobacter baumannii, leading to vaccine prototypes that generate a 12-fold higher antibody response than conventional formulations[5]. In oncology-related immunosuppression, these nano-vaccines enhance antigen presentation efficiency by up to 78% through targeted lymphoid delivery systems and biocompatible polymer encapsulation[6]. In a 2025 multicenter preclinical eva

FAQs

Why is antimicrobial resistance especially dangerous for immunosuppressed and oncologic patients?

The letter explains that immune dysfunction and extensive broad-spectrum antibiotic exposure create a vulnerable environment where resistant pathogens thrive, with high rates of multidrug-resistant infections and elevated mortality.

How do AI-engineered nano-vaccines aim to address AMR?

They combine AI-based antigen/epitope prediction with nanoparticle delivery to induce targeted immunity, including in compromised hosts, with reported improvements in epitope mapping precision and antibody titers.

What preclinical or translational evidence is cited for these nano-vaccines?

The text cites preclinical evaluations showing reduced resistant bloodstream infections in neutropenic models and a decline in resistant colonization within weeks after administration, alongside AI models trained on large microbial genome sets.

Sep 29, 2026

Upload by A glass of water